Analysts’ Top Healthcare Picks: Trulieve Cannabis (TCNNF), Avid Bioservices (CDMO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Trulieve Cannabis (TCNNF – Research Report), Avid Bioservices (CDMO – Research Report) and Ironwood Pharma (IRWD – Research Report) with bullish sentiments.

Trulieve Cannabis (TCNNF)

In a report released today, Alex Fuhrman from Craig-Hallum reiterated a Buy rating on Trulieve Cannabis, with a price target of $33.00. The company’s shares closed last Wednesday at $9.80.

According to TipRanks.com, Fuhrman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -4.8% and a 39.3% success rate. Fuhrman covers the NA sector, focusing on stocks such as Lindblad Expeditions Holdings, Barnes & Noble Education, and Penn National Gaming.

Currently, the analyst consensus on Trulieve Cannabis is a Moderate Buy with an average price target of $28.65.

See the top stocks recommended by analysts >>

Avid Bioservices (CDMO)

In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Avid Bioservices. The company’s shares closed last Thursday at $8.03.

According to TipRanks.com, Hewitt is a 3-star analyst with an average return of 1.7% and a 48.3% success rate. Hewitt covers the Healthcare sector, focusing on stocks such as Streamline Health Solutions, Champions Oncology, and BioLife Solutions.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Avid Bioservices with a $12.00 average price target.

Ironwood Pharma (IRWD)

Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Ironwood Pharma today. The company’s shares closed last Thursday at $10.85.

According to TipRanks.com, Knickerbocker is a 5-star analyst with an average return of 20.0% and a 69.1% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Fennec Pharmaceuticals, and Avadel Pharmaceuticals.

Currently, the analyst consensus on Ironwood Pharma is a Strong Buy with an average price target of $18.50, representing a 22.4% upside. In a report issued on February 15, Wells Fargo also maintained a Buy rating on the stock with a $20.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on TCNNF:

• Trulieve Reports Fourth Quarter and Full Year 2023 Results Highlighting Year End Momentum and Cash Generation
• Here’s What You Missed in Cannabis, Psychedelics This Week
• Rising High: Exclusive talk with cannabis market research firm BDSA
• Rising High: Exclusive talk with house of brands Carma HoldCo
• Rising High: Exclusive talk with drug manufacturer Optimi Health